Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership4,756,666 shares
Ownership 5.30%
State Street Corp ownership in TVTX / Travere Therapeutics, Inc.

2026-02-09 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,756,666 shares of Travere Therapeutics, Inc. (US:TVTX). This represents 5.3 percent ownership of the company. In their previous filing dated 2024-10-18 , State Street Corp had reported owning 2,736,696 shares, indicating an increase of 73.81 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-02-09 2026-02-09 13G 2,736,696 4,756,666 73.81 5.30 47.22
2024-10-18 2024-10-18 13G/A 5,352,345 2,736,696 -48.87 3.60 -49.44
2024-01-25 2024-01-25 13G/A 4,224,024 5,352,345 26.71 7.12 8.21
2023-02-06 2023-02-06 13G 4,224,024 6.58

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,959,988 203,322 4.27 147,361 -18.92 0.0051
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,756,666 1,538,827 47.82 181,752 136.33 0.0061
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,217,839 -265,337 -7.62 76,906 49.18 0.0027
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,483,176 -163,539 -4.48 51,551 -21.11 0.0019
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,646,715 -120,520 -3.20 65,349 -0.42 0.0027
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,767,235 1,030,539 37.66 65,625 71.41 0.0026
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,736,696 -773,981 -22.05 38,286 32.67 0.0016
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,510,677 -3,098,019 -46.88 28,858 -43.37 0.0013
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,608,696 1,256,351 23.47 50,953 5.89 0.0023
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 5,352,345 957,088 21.78 48,118 22.46 0.0023
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,395,257 -1,337,379 -23.33 39,294 -55.38 0.0022
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 5,732,636 1,364,759 31.25 88,053 -10.36 0.0046
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,367,877 143,853 3.41 98,234 10.58 0.0055
2023-05-15 2022-12-31 13F/A-99 TRAVERE THERAPEUTICS COM 89422G107 4,224,024 810,609 23.75 88,831 5.62 0.0052
2023-05-15 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,224,024 810,609 88,831 0.0052
2022-11-15 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,413,415 -193,750 -5.37 84,107 -3.77 0.0053
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,607,165 647,804 21.89 87,402 14.61 0.0052
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,959,361 72,284 2.50 76,263 -14.90 0.0038
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,887,077 104,754 3.76 89,615 32.82 0.0042
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,782,323 -671,536 -19.44 67,471 33.89 0.0036
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,453,859 1,014,332 41.58 50,392 -17.27 0.0027
2021-07-09 2021-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 2,439,527 2,439,527 60,915 0.0035
2021-05-17 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,439,527 2,439,527 60,915 0.0035
2021-02-16 2020-12-31 13F RETROPHIN COM 761299106 0 -1,920,415 -100.00 0 -100.00
2020-11-10 2020-09-30 13F RETROPHIN COM 761299106 1,920,415 82,309 4.48 35,451 -5.50 0.0024
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 1,838,106 112,534 6.52 37,516 49.01 0.0027
2020-06-19 2020-03-31 13F/A-1 RETROPHIN COM 761299106 1,725,572 -11,829 -0.68 25,176 2.05 0.0022
2020-05-11 2020-03-31 13F RETROPHIN COM 761299106 1,725,572 -11,829 25,176 2,210.9597
2020-02-06 2019-12-31 13F RETROPHIN COM 761299106 1,737,401 -415,022 -19.28 24,671 -1.11 0.0017
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 2,152,423 535,168 33.09 24,947 -23.22 0.0019
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 1,617,255 19,598 1.23 32,491 -10.13 0.0024
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 1,597,657 180,708 12.75 36,155 12.75 0.0028
2019-02-12 2018-12-31 13F RETROPHIN COM 761299106 1,416,949 -17,860 -1.24 32,066 -22.21 0.0029
2018-11-09 2018-09-30 13F RETROPHIN Common equity shares 761299106 1,434,809 -16,603 -1.14 41,223 4.18 0.0032
2018-08-14 2018-06-30 13F RETROPHIN Common equity shares 761299106 1,451,412 189,959 15.06 39,568 40.29 0.0033
2018-05-15 2018-03-31 13F RETROPHIN Common equity shares 761299106 1,261,453 17,430 1.40 28,205 7.59 0.0024
2018-02-14 2017-12-31 13F RETROPHIN Common equity shares 761299106 1,244,023 77,285 6.62 26,216 -9.71 0.0021
2017-11-14 2017-09-30 13F RETROPHIN Common equity shares 761299106 1,166,738 -21,814 -1.84 29,036 25.98 0.0025
2017-08-14 2017-06-30 13F RETROPHIN Common equity shares 761299106 1,188,552 -15,571 -1.29 23,049 3.69 0.0020
2017-05-15 2017-03-31 13F RETROPHIN Common equity shares 761299106 1,204,123 2,405 0.20 22,229 -2.29 0.0020
2017-02-09 2016-12-31 13F RETROPHIN Common equity shares 761299106 1,201,718 151,543 14.43 22,750 -3.20 0.0021
2017-01-13 2016-09-30 13F/A-1 RETROPHIN Common equity shares 761299106 1,050,175 74,752 7.66 23,503 35.29 0.0024
2016-11-14 2016-09-30 13F RETROPHIN Common equity shares 761299106 1,050,175 23,503
2016-08-12 2016-06-30 13F RETROPHIN Common equity shares 761299106 975,423 -154,963 -13.71 17,372 12.53 0.0019
2016-05-20 2016-03-31 13F/A-1 RETROPHIN Common equity shares 761299106 1,130,386 -103,221 -8.37 15,438 -35.12 0.0017
2016-05-12 2016-03-31 13F RETROPHIN Common equity shares 761299106 1,130,386 15,438
2016-02-16 2015-12-31 13F RETROPHIN Common equity shares 761299106 1,233,607 -165,379 -11.82 23,794 -16.05 0.0026
2015-11-16 2015-09-30 13F RETROPHIN Common equity shares 761299106 1,398,986 82,281 6.25 28,342 -35.07 0.0033
2015-08-13 2015-06-30 13F RETROPHIN Common equity shares 761299106 1,316,705 929,217 239.81 43,650 370.16 0.0047
2015-05-15 2015-03-31 13F RETROPHIN Common equity shares 761299106 387,488 95,742 32.82 9,284 159.91 0.0010
2015-02-11 2014-12-31 13F RETROPHIN Common equity shares 761299106 291,746 10,648 3.79 3,572 40.80 0.0004
2014-11-12 2014-09-30 13F/A-1 RETROPHIN Common equity shares 761299106 281,098 22,708 8.79 2,537 -16.41 0.0003
2014-11-10 2014-09-30 13F RETROPHIN Common equity shares 761299106 281,098 2,537
2014-08-12 2014-06-30 13F RETROPHIN Common equity shares 761299106 258,390 76,114 41.76 3,035 -21.70 0.0003
2014-05-15 2014-03-31 13F/A-1 RETROPHIN Common equity shares 761299106 182,276 182,276 3,876 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.